Excess fat in the liver (steatosis) is the root cause of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), which affect more than 1 billion people globally.
NAFLD and NASH are often asymptomatic. They are reversible when caught early, but can progress to advanced fibrosis, cirrhosis and cancer, which are irreversible. Thus, diagnosing these conditions as soon as possible is key.
Healthy liver |
Non-Alcoholic Fatty Liver Disease (NAFLD) |
Non-Alcoholic Steatohepatitis (NASH) |
Fibrosis |
Cirrhosis or cancer |
Invasive liver biopsy and expensive MRI have been the only options, meaning detection and monitoring for most patients is out of the question.
“If we could diagnose NAFLD-NASH early in the disease cycle, while it is still reversible, with a tool that is safe and easily accessible at the point of patient care, it could improve the health of millions of people and dramatically lower healthcare costs associated with later-stage acute disease management. ENDRA’s Thermo Acoustic Enhanced Ultrasound® (TAEUS®) liver device could be a game changer in the clinical care cycle of liver disease.”
Thermo-Acoustic Enhanced UltraSound will revolutionize what doctors can see and do at the patient bedside.
WATCH THE VIDEO >Learn how ENDRA is using ultrasound to help make difficult-to-diagnose diseases easier to find and treat.
WATCH THE VIDEO >See how TAEUS® is making it easier and more cost-effective than ever to assess and monitor fat in the liver.
WATCH THE VIDEO >TAEUS® will close gaps in a variety of other applications, such as visualizing tissue temperature during energy-based surgery and identifying arterial plaque or internal bleeding.
ENDRA operates a Quality Management System which complies with the requirements of ISO 13485:2016 & EN ISO 13485:2016 for the following scope:
Certificate number: MD 697226
Effective Date: 2022-04-02
Expiry Date: 2025-04-01